Signs and symptoms of Parkinson's disease explained

Signs and symptoms of Parkinson's disease are varied. Parkinson's disease affects movement, producing motor symptoms. Non-motor symptoms, which include dysautonomia, cognitive and neurobehavioral problems, and sensory and sleep difficulties, are also common. When other diseases mimic Parkinson's disease, they are categorized as parkinsonism.

Motor

See also: Parkinsonism.

Four motor symptoms are considered cardinal signs in PD: slowness of movement (bradykinesia), tremor, rigidity, and postural instability.[1] Typical for PD is an initial asymmetric distribution of these symptoms, where in the course of the disease, a gradual progression to bilateral symptoms develops, although some asymmetry usually persists. Other motor symptoms include gait and posture disturbances such as decreased arm swing, a forward-flexed posture, and the use of small steps when walking; speech and swallowing disturbances; and other symptoms such as a mask-like facial expression or small handwriting are examples of the range of common motor problems that can appear.[1]

Cardinal signs

Four motor signs are considered cardinal in PD: tremor, rigidity, bradykinesia, and postural instability (also referred to as parkinsonism).

In the late stages, postural instability is typical, which leads to impaired balance and frequent falls, and secondarily to bone fractures.[1] Instability is often absent in the initial stages, especially in younger people.[5] Up to 40% of the patients may experience falls and around 10% may have falls weekly, with the number of falls being related to the severity of PD. It is produced by a failure of postural reflexes, along other disease-related factors such as orthostatic hypotension or cognitive and sensory changes.[1]

Other motor symptoms

Other motor symptoms include:

Neuropsychiatric

See also: Neuronal death in Parkinson's Disease.

+Example of reported prevalences of mood problems in PD patients with dementia[8]
Mood problem Prevalence
Depression 58%
Apathy 54%
Anxiety 49%

Parkinson's disease causes neuropsychiatric disturbances, which mainly include cognitive disorders, mood disorders, and behavior problems, and can be as disabling as motor symptoms.[1]

Since L-Dopa, the widely used drug in Parkinson's disease treatment, is decarboxylated by aromatic L-amino acid decarboxylase (AADC), which is found in both dopaminergic and serotonergic neurons, it is possible for serotonergic neurons to convert L-Dopa into dopamine and generate excessive neuronal death by creating reactive oxygen species and quinoproteins. The association of serotonin with mood and cognition may explain some of the side-effects observed in patients treated with L-Dopa due to serotonin deficit.[9] [10]

In most cases, motor symptoms predominate at early PD stages, while cognitive disturbances (such as mild cognitive impairment or dementia) emerge later.[11] The onset of parkinsonism in PD relative to dementia is used as an arbitrary criterion to clinically distinguish Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) using a 'one-year rule'.[11] Dementia onset within 12-months of or at the same time as motor dysfunctions qualified as DLB, whereas in PDD, parkinsonism had to precede dementia by at least one year.[11]

Cognitive disturbances occur even in the initial stages of the disease in some cases. A very high proportion of patients have mild cognitive impairment as the disease advances.[1] Most common deficits in nondemented patients are:

Deficits tend to aggravate with time, developing in many cases into dementia. A person with PD has a six-fold increased risk of developing it,[1] and the overall rate in people with the disease is around 30%.[12] Moreover, prevalence of dementia increases in relation to disease duration, going up to 80%.[12] Dementia has been associated with a reduced quality of life in patients and caregivers, increased mortality, and a higher probability of moving to a nursing home.[12]

Cognitive problems and dementia are usually accompanied by behavior and mood alterations, although these kinds of changes are also more common in those patients without cognitive impairment than in the general population. Most frequent mood difficulties include:[1]

Obsessive–compulsive behaviors (also known as impulse-control disorders) such as craving, binge eating, hypersexuality, pathological gambling, punding, or others, can also appear in PD, and have been related to a dopamine dysregulation syndrome associated with the medications for the disease.[1]

Psychotic symptoms are common in PD, generally associated with dopamine therapy. Symptoms of psychosis, or impaired reality testing, are either hallucinations, typically visual, less commonly auditory, and rarely in other domains including tactile, gustatory, or olfactory, or delusions, that is, irrational beliefs. Hallucinations are generally stereotyped and without emotional content. Initially, patients usually have insight so that the hallucinations are benign in terms of their immediate impact, but have poor prognostic implications, with increased risk of dementia, worsened psychotic symptoms, and mortality. Delusions occur in about 5-10% of treated patients, and are considerably more disruptive, being paranoid in nature, of spousal infidelity or family abandonment. Psychosis is an independent risk factor for nursing-home placement.[23]

Hallucinations can occur in parkinsonian syndromes for a variety of reasons. An overlap exists between PD and dementia with Lewy bodies, so that where Lewy bodies are present in the visual cortex, hallucinations may result. Hallucinations can also be brought about by excessive dopaminergic stimulation. Most hallucinations are visual in nature, often formed as familiar people or animals, and are generally not threatening in nature. Some patients find them comforting; however, their caregivers often find this part of the disease most disturbing, and the occurrence of hallucinations is a major risk factor for hospitalisation. Treatment options consist of modifying the dosage of dopaminergic drugs taken each day, adding an antipsychotic drug such as quetiapine, or offering caregivers a psychosocial intervention to help them cope with the hallucinations.

Sleep

Sleep problems can be worsened by medications for PD, but they are a core feature of the disease.[1] Sleep dysfunction in PD has significant negative impacts on both patient and carer quality of life.[24] Some common symptoms are:

Perception

Autonomic

Gastrointestinal

Parkinson's Disease causes constipation and gastric dysmotility that is severe enough to endanger comfort and even health.[26] A factor in this is the appearance of Lewy bodies and Lewy neurites even before these affect the functioning of the substantia nigra in the neurons in the enteric nervous system that control gut functions.[27]

Neuro-ophthalmological

PD is related to different ophthalmological abnormalities produced by the neurological changes.[1] [28] Among them are:

Notes and References

  1. Jankovic J . Parkinson's disease: clinical features and diagnosis . J. Neurol. Neurosurg. Psychiatry . 79 . 4 . 368–76 . April 2008 . 18344392 . 10.1136/jnnp.2007.131045. free .
  2. Book: Cooper G, Eichhorn G, Rodnitzky RL . Parkinson's disease . Conn PM. Neuroscience in medicine. Humana Press. Totowa . 2008 . 508–512. 978-1-60327-454-8.
  3. Book: Banich MT, Compton RJ . Motor control . Cognitive neuroscience. Wadsworth, Cengage learning. Belmont, CA. 2011 . 108–44. 978-0-8400-3298-0.
  4. Book: Fung VS, Thompson PD . Rigidity and spasticity . Tolosa E, Jankovic JJ . Parkinson's disease and movement disorders. Lippincott Williams & Wilkins . Hagerstown, MD . 2007 . 504–13. 978-0-7817-7881-7.
  5. Samii A, Nutt JG, Ransom BR . Parkinson's disease . Lancet . 363 . 9423 . 1783–93 . May 2004 . 15172778 . 10.1016/S0140-6736(04)16305-8 . 35364322 .
  6. Rodriguez-Oroz MC, Jahanshahi M, Krack P, etal . Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms . Lancet Neurol . 8 . 12 . 1128–39 . December 2009 . 19909911 . 10.1016/S1474-4422(09)70293-5 . 16415964 .
  7. Lepoutre A, Devos D, Blanchard-Dauphin A, etal . A specific clinical pattern of camptocormia in Parkinson's disease . J. Neurol. Neurosurg. Psychiatry . 77 . 11 . 1229–34 . 2006 . 16735399 . 10.1136/jnnp.2005.083998 . 2077366.
  8. Aarsland D, Brønnick K, Ehrt U, etal . Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress . Journal of Neurology, Neurosurgery, and Psychiatry . 78 . 1 . 36–42 . January 2007 . 16820421 . 2117797 . 10.1136/jnnp.2005.083113.
  9. Stansley, B. J., & Yamamoto, B. K. (2012). L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology, 67, 243–251. doi:10.1016/j.neuropharm.2012.11.010
  10. Stansley, B. J., & Yamamoto, B. K. (2015). L-Dopa and Brain Serotonin System Dysfunction. Toxics, 3(1), 75–88. doi:10.3390/toxics3010075
  11. Saeed. U. Compagnone. J. Aviv. RI. Strafella. AP. Black. SE. Lang. AE. Masellis. M. Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.. Translational Neurodegeneration. 2017. 6. 8. 8. 28360997. 5370489. 10.1186/s40035-017-0076-6. free.
  12. Caballol N, Martí MJ, Tolosa E . Cognitive dysfunction and dementia in Parkinson disease . Mov. Disord. . 22 . Suppl 17. S358–66 . September 2007 . 18175397 . 10.1002/mds.21677 . 3229727 .
  13. 17987654. A systematic review of prevalence studies of depression in Parkinson's disease.. Reinders. JS. Jan 2008. Movement Disorders. 10.1002/mds.21803. 23. 2. 183–9; quiz 313. 1956/4068. 16613346 . free.
  14. Lieberman A. Depression in Parkinson's disease -- a review. Acta Neurologica Scandinavica. 113. 1. 1–8. January 2006. 16367891. 10.1111/j.1600-0404.2006.00536.x. 35349675 . free.
  15. Ishihara L, Brayne C . A systematic review of depression and mental illness preceding Parkinson's disease . Acta Neurologica Scandinavica . 113 . 4 . 211–20 . April 2006 . 16542159 . 10.1111/j.1600-0404.2006.00579.x. 249341 .
  16. 25995056. Depression and subsequent risk of Parkinson disease: A nationwide cohort study.. Gustafsson. H. June 2015. Neurology. 10.1212/WNL.0000000000001684. 84. 24. 4478031. 2422–9.
  17. McDonald W . Richard . IH . Delong . MR. Prevalence, Etiology, and Treatment of Depression in Parkinson's Disease . Biol Psychiatry. 54 . 3. 363–375 . 2003. 12893111. 10.1016/S0006-3223(03)00530-4. 45520438 .
  18. Parkinson disease: Depression—risk factor or early symptom in Parkinson disease?. Nature Reviews Neurology. 432–433. 11. 8. 10.1038/nrneurol.2015.126. 26215622. Albert F.. Leentjens. 2015. 11364065 .
  19. Modeling depression in Parkinson disease Disease-specific and nonspecific risk factors. Neurology. 2013-09-17. 0028-3878. 3795592. 23946309. 1036–1043. 81. 12. 10.1212/WNL.0b013e3182a4a503. Albert F. G.. Leentjens. Anja J. H.. Moonen. Kathy. Dujardin. Laura. Marsh. Pablo. Martinez-Martin. Irene H.. Richard. Sergio E.. Starkstein. Sebastian. Köhler.
  20. Menza, Matthew Combating Depression in Parkinson's Disease. Parkinson's Disease Foundation News & Review. Spring 2009.
  21. Menza MA. Psychiatric symptoms associated with Parkinson disease. Drug Benefit Trends. 2010;22:58-60.
  22. Book: Non-motor features of Parkinson's disease. The National Collaborating Centre for Chronic Conditions . Parkinson's Disease . http://guidance.nice.org.uk/CG35/Guidance/pdf/English . Royal College of Physicians. London . 2006 . 978-1-86016-283-1 . 113–33 .
  23. Friedman JH . Parkinson's disease psychosis 2010: A review article . Parkinsonism Relat Disord . 16. 9. 553–60. June 2010 . 20538500 . 10.1016/j.parkreldis.2010.05.004 .
  24. Hunt . Jeremy . Coulson . Elizabeth J. . Rajnarayanan . Rajendram . Oster . Henrik . Videnovic . Aleksandar . Rawashdeh . Oliver . 2022-01-09 . Sleep and circadian rhythms in Parkinson's disease and preclinical models . Molecular Neurodegeneration . 17 . 1 . 2 . 10.1186/s13024-021-00504-w . 1750-1326 . 8744293 . 35000606 . free .
  25. Gupta AK, Bluhm R . Seborrheic dermatitis . Journal of the European Academy of Dermatology and Venereology . 18 . 1 . 13–26; quiz 19–20 . January 2004 . 14678527 . 10.1111/j.1468-3083.2004.00693.x. 45180745 .
  26. Pfeiffer RF . Gastrointestinal dysfunction in Parkinson's disease . Lancet Neurology . 2 . 2 . 107–16 . February 2003 . 12849267 . 10.1016/S1474-4422(03)00307-7. 21009040 .
  27. Lebouvier T, Chaumette T, Paillusson S, etal . The second brain and Parkinson's disease . The European Journal of Neuroscience . 30 . 5 . 735–41 . September 2009 . 19712093 . 10.1111/j.1460-9568.2009.06873.x. 1024997 .
  28. Armstrong RA . Visual signs and symptoms of Parkinson's disease . Clin Exp Optom . 91 . 2 . 129–38 . March 2008 . 18271776 . 10.1111/j.1444-0938.2007.00211.x . 26202780 .
  29. 22490323 . 10.1001/archneurol.2012.70 . 69 . 8 . Pervasive ocular tremor in patients with Parkinson disease . 2012 . Gitchel GT, Wetzel PA, Baron MS . Arch Neurol . 1011–7.
  30. Uc EY. Rizzo. M. Anderson. SW. Sparks. J. Rodnitzky. RL. Dawson. JD. Impaired visual search in drivers with Parkinson's disease. Annals of Neurology. 2006 . 407–13. 16969860. 4. 10.1002/ana.20958. 60. 40915704 .